Tasly Pharmaceutical Group Co Ltd (600535) - Total Assets
Based on the latest financial reports, Tasly Pharmaceutical Group Co Ltd (600535) holds total assets worth CN¥15.69 Billion CNY (≈ $2.30 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Tasly Pharmaceutical Group Co Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Tasly Pharmaceutical Group Co Ltd - Total Assets Trend (1999–2025)
This chart illustrates how Tasly Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore Tasly Pharmaceutical Group Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Tasly Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Tasly Pharmaceutical Group Co Ltd's total assets of CN¥15.69 Billion consist of 53.7% current assets and 46.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.4% |
| Accounts Receivable | CN¥2.51 Billion | 16.3% |
| Inventory | CN¥1.43 Billion | 9.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥2.11 Billion | 13.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Tasly Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Tasly Pharmaceutical Group Co Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tasly Pharmaceutical Group Co Ltd's current assets represent 53.7% of total assets in 2025, a decrease from 69.2% in 1999.
- Cash Position: Cash and equivalents constituted 9.4% of total assets in 2025, down from 34.3% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 4.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 16.3% of total assets.
Tasly Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Tasly Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Eris Lifesciences Limited
NSE:ERIS
|
India | Rs71.60 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
Taiwan | NT$106.15 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
Tasly Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.72 | 3.00 | 5.97 |
| Quick Ratio | 3.09 | 2.34 | 4.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥6.30 Billion | CN¥4.91 Billion | CN¥6.76 Billion |
Tasly Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Tasly Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.69 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | 2.4% |
| Total Assets | CN¥15.34 Billion |
| Market Capitalization | $3.08 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Tasly Pharmaceutical Group Co Ltd's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tasly Pharmaceutical Group Co Ltd's assets grew by 2.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tasly Pharmaceutical Group Co Ltd (1999–2025)
The table below shows the annual total assets of Tasly Pharmaceutical Group Co Ltd from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥15.34 Billion ≈ $2.24 Billion |
+2.43% |
| 2024-12-31 | CN¥14.98 Billion ≈ $2.19 Billion |
-10.40% |
| 2023-12-31 | CN¥16.71 Billion ≈ $2.45 Billion |
+1.73% |
| 2022-12-31 | CN¥16.43 Billion ≈ $2.40 Billion |
-0.67% |
| 2021-12-31 | CN¥16.54 Billion ≈ $2.42 Billion |
+0.29% |
| 2020-12-31 | CN¥16.49 Billion ≈ $2.41 Billion |
-31.31% |
| 2019-12-31 | CN¥24.01 Billion ≈ $3.51 Billion |
-4.61% |
| 2018-12-31 | CN¥25.17 Billion ≈ $3.68 Billion |
+16.91% |
| 2017-12-31 | CN¥21.53 Billion ≈ $3.15 Billion |
+25.72% |
| 2016-12-31 | CN¥17.13 Billion ≈ $2.51 Billion |
+11.12% |
| 2015-12-31 | CN¥15.41 Billion ≈ $2.26 Billion |
+19.28% |
| 2014-12-31 | CN¥12.92 Billion ≈ $1.89 Billion |
+26.53% |
| 2013-12-31 | CN¥10.21 Billion ≈ $1.49 Billion |
+36.42% |
| 2012-12-31 | CN¥7.49 Billion ≈ $1.10 Billion |
+12.84% |
| 2011-12-31 | CN¥6.63 Billion ≈ $970.79 Million |
+21.67% |
| 2010-12-31 | CN¥5.45 Billion ≈ $797.90 Million |
+35.46% |
| 2009-12-31 | CN¥4.03 Billion ≈ $589.03 Million |
+16.74% |
| 2008-12-31 | CN¥3.45 Billion ≈ $504.57 Million |
+11.43% |
| 2007-12-31 | CN¥3.09 Billion ≈ $452.80 Million |
-5.08% |
| 2006-12-31 | CN¥3.26 Billion ≈ $477.01 Million |
+18.35% |
| 2005-12-31 | CN¥2.75 Billion ≈ $403.06 Million |
+25.14% |
| 2004-12-31 | CN¥2.20 Billion ≈ $322.08 Million |
+23.85% |
| 2003-12-31 | CN¥1.78 Billion ≈ $260.07 Million |
+42.10% |
| 2002-12-31 | CN¥1.25 Billion ≈ $183.02 Million |
+110.06% |
| 2001-12-31 | CN¥595.39 Million ≈ $87.12 Million |
+41.60% |
| 2000-12-31 | CN¥420.47 Million ≈ $61.53 Million |
+20.02% |
| 1999-12-31 | CN¥350.34 Million ≈ $51.27 Million |
-- |
About Tasly Pharmaceutical Group Co Ltd
Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical… Read more